BACKGROUND: Millions of postmenopausal women use multivitamins, often believing that supplements prevent chronic diseases such as cancer and cardiovascular disease (CVD). Therefore, we decided to examine associations between multivitamin use and risk of cancer, CVD, and mortality in postmenopausal women. METHODS: The study included 161 808 participants from the Women's Health Initiative clinical trials (N = 68 132 in 3 overlapping trials of hormone therapy, dietary modification, and calcium and vitamin D supplements) or an observational study (N = 93 676). Detailed data were collected on multivitamin use at baseline and follow-up time points. Study enrollment occurred between 1993 and 1998; the women were followed up for a median of 8.0 years in the clinical trials and 7.9 years in the observational study. Disease end points were collected through 2005. We documented cancers of the breast (invasive), colon/rectum, endometrium, kidney, bladder, stomach, ovary, and lung; CVD (myocardial infarction, stroke, and venous thromboembolism); and total mortality. RESULTS: A total of 41.5% of the participants used multivitamins. After a median of 8.0 years of follow-up in the clinical trial cohort and 7.9 years in the observational study cohort, 9619 cases of breast, colorectal, endometrial, renal, bladder, stomach, lung, or ovarian cancer; 8751 CVD events; and 9865 deaths were reported. Multivariate-adjusted analyses revealed no association of multivitamin use with risk of cancer (hazard ratio [HR], 0.98, and 95% confidence interval [CI], 0.91-1.05 for breast cancer; HR, 0.99, and 95% CI, 0.88-1.11 for colorectal cancer; HR, 1.05, and 95% CI, 0.90-1.21 for endometrial cancer; HR, 1.0, and 95% CI, 0.88-1.13 for lung cancer; and HR, 1.07, and 95% CI, 0.88-1.29 for ovarian cancer); CVD (HR, 0.96, and 95% CI, 0.89-1.03 for myocardial infarction; HR, 0.99, and 95% CI, 0.91-1.07 for stroke; and HR, 1.05, and 95% CI, 0.85-1.29 for venous thromboembolism); or mortality (HR, 1.02, and 95% CI, 0.97-1.07). CONCLUSION: After a median follow-up of 8.0 and 7.9 years in the clinical trial and observational study cohorts, respectively, the Women's Health Initiative study provided convincing evidence that multivitamin use has little or no influence on the risk of common cancers, CVD, or total mortality in postmenopausal women.
BACKGROUND: Millions of postmenopausal women use multivitamins, often believing that supplements prevent chronic diseases such as cancer and cardiovascular disease (CVD). Therefore, we decided to examine associations between multivitamin use and risk of cancer, CVD, and mortality in postmenopausal women. METHODS: The study included 161 808 participants from the Women's Health Initiative clinical trials (N = 68 132 in 3 overlapping trials of hormone therapy, dietary modification, and calcium and vitamin D supplements) or an observational study (N = 93 676). Detailed data were collected on multivitamin use at baseline and follow-up time points. Study enrollment occurred between 1993 and 1998; the women were followed up for a median of 8.0 years in the clinical trials and 7.9 years in the observational study. Disease end points were collected through 2005. We documented cancers of the breast (invasive), colon/rectum, endometrium, kidney, bladder, stomach, ovary, and lung; CVD (myocardial infarction, stroke, and venous thromboembolism); and total mortality. RESULTS: A total of 41.5% of the participants used multivitamins. After a median of 8.0 years of follow-up in the clinical trial cohort and 7.9 years in the observational study cohort, 9619 cases of breast, colorectal, endometrial, renal, bladder, stomach, lung, or ovarian cancer; 8751 CVD events; and 9865 deaths were reported. Multivariate-adjusted analyses revealed no association of multivitamin use with risk of cancer (hazard ratio [HR], 0.98, and 95% confidence interval [CI], 0.91-1.05 for breast cancer; HR, 0.99, and 95% CI, 0.88-1.11 for colorectal cancer; HR, 1.05, and 95% CI, 0.90-1.21 for endometrial cancer; HR, 1.0, and 95% CI, 0.88-1.13 for lung cancer; and HR, 1.07, and 95% CI, 0.88-1.29 for ovarian cancer); CVD (HR, 0.96, and 95% CI, 0.89-1.03 for myocardial infarction; HR, 0.99, and 95% CI, 0.91-1.07 for stroke; and HR, 1.05, and 95% CI, 0.85-1.29 for venous thromboembolism); or mortality (HR, 1.02, and 95% CI, 0.97-1.07). CONCLUSION: After a median follow-up of 8.0 and 7.9 years in the clinical trial and observational study cohorts, respectively, the Women's Health Initiative study provided convincing evidence that multivitamin use has little or no influence on the risk of common cancers, CVD, or total mortality in postmenopausal women.
Authors: Eunyoung Cho; David J Hunter; Donna Spiegelman; Demetrius Albanes; W Lawrence Beeson; Piet A van den Brandt; Graham A Colditz; Diane Feskanich; Aaron R Folsom; Gary E Fraser; Jo L Freudenheim; Edward Giovannucci; R Alexandra Goldbohm; Saxon Graham; Anthony B Miller; Thomas E Rohan; Thomas A Sellers; Jarmo Virtamo; Walter C Willett; Stephanie A Smith-Warner Journal: Int J Cancer Date: 2006-02-15 Impact factor: 7.396
Authors: Alice H Lichtenstein; Lawrence J Appel; Michael Brands; Mercedes Carnethon; Stephen Daniels; Harold A Franch; Barry Franklin; Penny Kris-Etherton; William S Harris; Barbara Howard; Njeri Karanja; Michael Lefevre; Lawrence Rudel; Frank Sacks; Linda Van Horn; Mary Winston; Judith Wylie-Rosett Journal: Circulation Date: 2006-06-19 Impact factor: 29.690
Authors: I-Min Lee; Nancy R Cook; J Michael Gaziano; David Gordon; Paul M Ridker; Joann E Manson; Charles H Hennekens; Julie E Buring Journal: JAMA Date: 2005-07-06 Impact factor: 56.272
Authors: Lawrence H Kushi; Tim Byers; Colleen Doyle; Elisa V Bandera; Marji McCullough; Anne McTiernan; Ted Gansler; Kimberly S Andrews; Michael J Thun Journal: CA Cancer J Clin Date: 2006 Sep-Oct Impact factor: 508.702
Authors: Esther K Wei; Edward Giovannucci; Jacob Selhub; Charles S Fuchs; Susan E Hankinson; Jing Ma Journal: J Natl Cancer Inst Date: 2005-05-04 Impact factor: 13.506
Authors: Ross L Prentice; Robert Langer; Marcia L Stefanick; Barbara V Howard; Mary Pettinger; Garnet Anderson; David Barad; J David Curb; Jane Kotchen; Lewis Kuller; Marian Limacher; Jean Wactawski-Wende Journal: Am J Epidemiol Date: 2005-07-20 Impact factor: 4.897
Authors: Ross L Prentice; Robert D Langer; Marcia L Stefanick; Barbara V Howard; Mary Pettinger; Garnet L Anderson; David Barad; J David Curb; Jane Kotchen; Lewis Kuller; Marian Limacher; Jean Wactawski-Wende Journal: Am J Epidemiol Date: 2006-02-16 Impact factor: 4.897
Authors: Bernard F Cole; John A Baron; Robert S Sandler; Robert W Haile; Dennis J Ahnen; Robert S Bresalier; Gail McKeown-Eyssen; Robert W Summers; Richard I Rothstein; Carol A Burke; Dale C Snover; Timothy R Church; John I Allen; Douglas J Robertson; Gerald J Beck; John H Bond; Tim Byers; Jack S Mandel; Leila A Mott; Loretta H Pearson; Elizabeth L Barry; Judy R Rees; Norman Marcon; Fred Saibil; Per Magne Ueland; E Robert Greenberg Journal: JAMA Date: 2007-06-06 Impact factor: 56.272
Authors: Jung Eun Lee; Walter C Willett; Charles S Fuchs; Stephanie A Smith-Warner; Kana Wu; Jing Ma; Edward Giovannucci Journal: Am J Clin Nutr Date: 2011-01-26 Impact factor: 7.045
Authors: Marco Vinceti; Gabriele Dennert; Catherine M Crespi; Marcel Zwahlen; Maree Brinkman; Maurice P A Zeegers; Markus Horneber; Roberto D'Amico; Cinzia Del Giovane Journal: Cochrane Database Syst Rev Date: 2014-03-30
Authors: Adriana M Coletta; Susan K Peterson; Leticia A Gatus; Kate J Krause; Susan M Schembre; Susan C Gilchrist; Mala Pande; Eduardo Vilar; Y Nancy You; Miguel A Rodriguez-Bigas; Larkin L Strong; Patrick M Lynch; Karen H Lu; Karen Basen-Engquist Journal: Fam Cancer Date: 2019-06-24 Impact factor: 2.375
Authors: Todd M Gibson; Stephanie J Weinstein; Ruth M Pfeiffer; Albert R Hollenbeck; Amy F Subar; Arthur Schatzkin; Susan T Mayne; Rachael Stolzenberg-Solomon Journal: Am J Clin Nutr Date: 2011-08-03 Impact factor: 7.045
Authors: Roland B Walter; Theodore M Brasky; Filippo Milano; Emily White Journal: Cancer Epidemiol Biomarkers Prev Date: 2011-07-29 Impact factor: 4.254